November 4, 2021

Quarterly Financial Summary(For the first six months of the fiscal year ending March 31, 2022)[Under Japanese GAAP](Consolidated)
Listed Company: Zeria Pharmaceutical Co., Ltd.
(Stock Exchange: First Section of Tokyo Stock Exchange)
Code Number: 4559
(URL: https://www.zeria.co.jp/)
Representative: Mitsuhiro Ibe, Representative Director, President & COO
Person in charge of reference: Tomoyuki Nishizawa, Director, Public Relations Division
TEL (03) 3661-1039
Scheduled date to submit the Quarterly Securities Report:
November 8, 2021
Scheduled date to commence dividend payments:
December 1, 2021
Preparation of supplementary documents to the quarterly financial results:
Yes
Holding of quarterly financial results presentation:
Yes (for analysts, institutional investors and the press)(Amounts under a million yen are truncated.)

1. Consolidated Financial Highlights (April 1, 2021 through September 30, 2021)(1) Consolidated Financial Results (cumulative)(Percentage figures indicate changes from the same period of the previous year.)
Profit attributable toOperating profit
Ordinary profit
owners of parentNet sales
Six months ended

Million yen%

Million yen%

Million yen%

Million yen%

September 30, 2021

28,606

12.1

2,672

67.2

3,116

138.4

2,115

52.4

September 30, 2020

25,521–

1,598–

1,307

–

1,388

–

Note: Comprehensive income: For the six months ended September 30, 2021: 2,194 million yen [10.9%]
For the six months ended September 30, 2020: 1,978 million yen [–%]

Basic earnings
per share

Diluted earnings
per share

Six months ended

YenYenSeptember 30, 2021

46.65

–

September 30, 2020

30.05

–

Note: The Company has applied the “Accounting Standard for Revenue Recognition” (ASBJ Statement No. 29, March 31, 2020) and relevant revised
ASBJ regulations from the start of the first quarter of the fiscal year ending March 31, 2022, and each figure for the six months ended
September 30, 2020, is the figure after retrospectively applying the accounting standard and relevant revised ASBJ regulations. Consequently,
the percentage of year-on-year change of each figure for the six months ended September 30, 2020, is not shown.

(2) Consolidated Financial Position
Total assets
As ofNet assets

Equity ratio

Net assets per share

Million yen

Million yen%

Yen

September 30, 2021

123,673

56,41645.5

1,246.90

March 31, 2021

121,860

56,15245.9

1,225.09

Reference: Equity: As of September 30, 2021: 56,235 million yen
As of March 31, 2021: 55,985 million yen
Note: The Company has applied the “Accounting Standard for Revenue Recognition” (ASBJ Statement No. 29, March 31, 2020) and relevant revised
ASBJ regulations from the start of the first quarter of the fiscal year ending March 31, 2022, and each figure as of March 31, 2021, is the figure
after retrospectively applying the accounting standard and relevant revised ASBJ regulations.

2. Dividends
Annual dividends
First quarter

Second quarter

Third quarter

Year-end

Total

Yen

Yen

Yen

Yen

Yen

–

17.00

–

17.00

34.00

–

17.00
–

17.00

34.00

Year ended
March 31, 2021
Year ending
March 31, 2022
Year ending
March 31, 2022(Forecast)

Note: Revision of the forecast of dividends most recently announced: None

3. Consolidated Financial Forecast for the Fiscal Year Ending March 31, 2022 (April 1, 2021 through March 31, 2022)
Net sales

Full year(Percentage figures indicate year-on-year changes.)
Profit attributable toBasic earnings
Ordinary profit
owners of parentper share

Operating profit

Million yen%

Million yen%

Million yen%

Million yen%

Yen

60,000

13.7

5,300

52.5

5,200

62.1

3,700

17.7

81.80

Note: Revision of the financial forecast most recently announced: None
Year-on-year changes are presented in comparison with figures from the previous fiscal year after retrospective adjustments as retrospective
adjustments were carried out due to changes in accounting policies.

* Notes(1) Significant changes of subsidiaries during the six months ended September 30, 2021 (changes in specified subsidiaries
resulting in changes in scope of consolidation): None
Inclusion: – (Company name: –)Exclusion: – (Company name: –)(2) Application of special accounting for preparing the quarterly consolidated financial statements: Yes(3) Changes in accounting policies, changes in accounting estimates, and restatement of prior period financial statements aftererror corrections
1) Changes in accounting policies due to revisions to accounting standards and other regulations: Yes
2) Changes in accounting policies due to other reasons: None
3) Changes in accounting estimates: None
4) Restatement of prior period financial statements after error corrections: None

(4) Number of shares issued (common shares)
1) Number of shares issued as of the end of the period (including treasury shares):
As of September 30, 2021: 53,119,190 shares
As of March 31, 2021: 53,119,190 shares
2) Number of treasury shares as of the end of the period:
As of September 30, 2021: 8,018,749 shares
As of March 31, 2021: 7,420,461 shares
3) Average number of shares during the period (cumulative from the beginning of the fiscal year):
For the six months ended September 30, 2021: 45,360,392 shares
For the six months ended September 30, 2020: 46,206,490 shares* Quarterly Financial Summary Is Exempt from Quarterly Review Conducted by Certified Public Accountants or
An Audit Corporation.

* Cautionary Statement with Respect to Appropriate Use of Financial Forecast and Other Special Matters
The description about the future including the projection in this document is based on information available to theCompany at present and certain presumptions which the Company considers reasonable. Consequently, any descriptions
herein do not constitute assurances regarding actual results by the Company. The actual results for future terms may differ
from the information in this document due to various factors.